ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Kidney Cancer Drugs Market Research Report 2025
Published Date: August 2025
|
Report Code: QYRE-Auto-18N1254
Home | Market Reports | Business & Industrial| Pharmaceuticals & Biotech
Global Kidney Cancer Drugs Market Insights Forecast to 2028
BUY CHAPTERS

Global Kidney Cancer Drugs Market Research Report 2025

Code: QYRE-Auto-18N1254
Report
August 2025
Pages:125
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
Bayer
Roche
GlaxoSmithKline PLC
Novartis
Pfizer Inc
Abbott Laboratories
Active Biotech
Amgen Inc
Argos Therapeutics
ArQule Inc
AVEO Pharmaceuticals
Bionomics Ltd
Bristol–Myers Squibb
Cerulean Pharma
Exelixis Inc
Immatics Biotechnologies
Immunicum
Ono Pharmaceutical
Onyx Therapeutics
Oxford BioMedica
Prometheus Laboratories
Seattle Genetics
Taiwan Liposome
Tracon Pharmaceuticals
Wilex
Genentech Inc

Kidney Cancer Drugs Market Size

The global market for Kidney Cancer Drugs was valued at US$ 4439 million in the year 2024 and is projected to reach a revised size of US$ 5936 million by 2031, growing at a CAGR of 4.3% during the forecast period.

Kidney Cancer Drugs Market

Kidney Cancer Drugs Market

Kidney cancer, also known as renal cancer, is a type of cancer that starts in the cells in the kidney. The two most common types of kidney cancer are renal cell carcinoma (RCC) and transitional cell carcinoma (TCC) of the renal pelvis. These names reflect the type of cell from which the cancer developed. The different types of kidney cancer (such as RCC and TCC) develop in different ways, meaning that the diseases have different long term outcomes, and need to be staged and treated in different ways. RCC is responsible for approximately 80% of primary renal cancers, and TCC accounts the majority of the remainder.
Biological therapies are drugs which are used to kill cancer cells or stop them from growing. Biological therapies are used to try to shrink or control advanced kidney cancer and help people to live longer. You may be given biological therapies for kidney cancer that has already spread, or is at high-risk of coming back after surgery.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Kidney Cancer Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Kidney Cancer Drugs.
The Kidney Cancer Drugs market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Kidney Cancer Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Kidney Cancer Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Kidney Cancer Drugs Market Report

Report Metric Details
Report Name Kidney Cancer Drugs Market
Accounted market size in year US$ 4439 million
Forecasted market size in 2031 US$ 5936 million
CAGR 4.3%
Base Year year
Forecasted years 2025 - 2031
Segment by Type
  • Angiogenesis Inhibitors
  • mTOR Inhibitors
  • Monoclonal Antibodies
  • Cytokine Immunotherapy (IL-2)
Segment by Application
  • Renal Cell Carcinoma (RCC)
  • Transitional Cell Carcinoma (TCC)
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company Bayer, Roche, GlaxoSmithKline, Novartis, Pfizer, Abbott Laboratories, Active Biotech, Amgen, Argos Therapeutics, ArQule, AVEO Pharmaceuticals, Bionomics, Bristol-Myers Squibb, Cerulean Pharma, Exelixis, Genentech, immatics biotechnologies, Immunicum, Ono Pharmaceutical, Onyx Therapeutics, Oxford BioMedica, Prometheus Laboratories, Seattle Genetics, Taiwan Liposome, Tracon Pharmaceuticals, Wilex
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Kidney Cancer Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Kidney Cancer Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

How fast is Kidney Cancer Drugs Market growing?

Ans: The Kidney Cancer Drugs Market witnessing a CAGR of 4.3% during the forecast period 2025-2031.

What is the Kidney Cancer Drugs Market size in 2031?

Ans: The Kidney Cancer Drugs Market size in 2031 will be US$ 5936 million.

Who are the main players in the Kidney Cancer Drugs Market report?

Ans: The main players in the Kidney Cancer Drugs Market are Bayer, Roche, GlaxoSmithKline, Novartis, Pfizer, Abbott Laboratories, Active Biotech, Amgen, Argos Therapeutics, ArQule, AVEO Pharmaceuticals, Bionomics, Bristol-Myers Squibb, Cerulean Pharma, Exelixis, Genentech, immatics biotechnologies, Immunicum, Ono Pharmaceutical, Onyx Therapeutics, Oxford BioMedica, Prometheus Laboratories, Seattle Genetics, Taiwan Liposome, Tracon Pharmaceuticals, Wilex

What are the Application segmentation covered in the Kidney Cancer Drugs Market report?

Ans: The Applications covered in the Kidney Cancer Drugs Market report are Renal Cell Carcinoma (RCC), Transitional Cell Carcinoma (TCC)

What are the Type segmentation covered in the Kidney Cancer Drugs Market report?

Ans: The Types covered in the Kidney Cancer Drugs Market report are Angiogenesis Inhibitors, mTOR Inhibitors, Monoclonal Antibodies, Cytokine Immunotherapy (IL-2)

1 Kidney Cancer Drugs Market Overview
1.1 Product Definition
1.2 Kidney Cancer Drugs by Type
1.2.1 Global Kidney Cancer Drugs Market Value Comparison by Type (2024 VS 2031)
1.2.2 Angiogenesis Inhibitors
1.2.3 mTOR Inhibitors
1.2.4 Monoclonal Antibodies
1.2.5 Cytokine Immunotherapy (IL-2)
1.3 Kidney Cancer Drugs by Application
1.3.1 Global Kidney Cancer Drugs Market Value by Application (2024 VS 2031)
1.3.2 Renal Cell Carcinoma (RCC)
1.3.3 Transitional Cell Carcinoma (TCC)
1.4 Global Kidney Cancer Drugs Market Size Estimates and Forecasts
1.4.1 Global Kidney Cancer Drugs Revenue 2020-2031
1.4.2 Global Kidney Cancer Drugs Sales 2020-2031
1.4.3 Global Kidney Cancer Drugs Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Kidney Cancer Drugs Market Competition by Manufacturers
2.1 Global Kidney Cancer Drugs Sales Market Share by Manufacturers (2020-2025)
2.2 Global Kidney Cancer Drugs Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Kidney Cancer Drugs Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Kidney Cancer Drugs, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Kidney Cancer Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Kidney Cancer Drugs, Product Type & Application
2.7 Global Key Manufacturers of Kidney Cancer Drugs, Date of Enter into This Industry
2.8 Global Kidney Cancer Drugs Market Competitive Situation and Trends
2.8.1 Global Kidney Cancer Drugs Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Kidney Cancer Drugs Players Market Share by Revenue
2.8.3 Global Kidney Cancer Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Kidney Cancer Drugs Market Scenario by Region
3.1 Global Kidney Cancer Drugs Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Kidney Cancer Drugs Sales by Region: 2020-2031
3.2.1 Global Kidney Cancer Drugs Sales by Region: 2020-2025
3.2.2 Global Kidney Cancer Drugs Sales by Region: 2026-2031
3.3 Global Kidney Cancer Drugs Revenue by Region: 2020-2031
3.3.1 Global Kidney Cancer Drugs Revenue by Region: 2020-2025
3.3.2 Global Kidney Cancer Drugs Revenue by Region: 2026-2031
3.4 North America Kidney Cancer Drugs Market Facts & Figures by Country
3.4.1 North America Kidney Cancer Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Kidney Cancer Drugs Sales by Country (2020-2031)
3.4.3 North America Kidney Cancer Drugs Revenue by Country (2020-2031)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Kidney Cancer Drugs Market Facts & Figures by Country
3.5.1 Europe Kidney Cancer Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Kidney Cancer Drugs Sales by Country (2020-2031)
3.5.3 Europe Kidney Cancer Drugs Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Kidney Cancer Drugs Market Facts & Figures by Region
3.6.1 Asia Pacific Kidney Cancer Drugs Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Kidney Cancer Drugs Sales by Region (2020-2031)
3.6.3 Asia Pacific Kidney Cancer Drugs Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Kidney Cancer Drugs Market Facts & Figures by Country
3.7.1 Latin America Kidney Cancer Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Kidney Cancer Drugs Sales by Country (2020-2031)
3.7.3 Latin America Kidney Cancer Drugs Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Kidney Cancer Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Kidney Cancer Drugs Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Kidney Cancer Drugs Sales by Country (2020-2031)
3.8.3 Middle East and Africa Kidney Cancer Drugs Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Kidney Cancer Drugs Sales by Type (2020-2031)
4.1.1 Global Kidney Cancer Drugs Sales by Type (2020-2025)
4.1.2 Global Kidney Cancer Drugs Sales by Type (2026-2031)
4.1.3 Global Kidney Cancer Drugs Sales Market Share by Type (2020-2031)
4.2 Global Kidney Cancer Drugs Revenue by Type (2020-2031)
4.2.1 Global Kidney Cancer Drugs Revenue by Type (2020-2025)
4.2.2 Global Kidney Cancer Drugs Revenue by Type (2026-2031)
4.2.3 Global Kidney Cancer Drugs Revenue Market Share by Type (2020-2031)
4.3 Global Kidney Cancer Drugs Price by Type (2020-2031)
5 Segment by Application
5.1 Global Kidney Cancer Drugs Sales by Application (2020-2031)
5.1.1 Global Kidney Cancer Drugs Sales by Application (2020-2025)
5.1.2 Global Kidney Cancer Drugs Sales by Application (2026-2031)
5.1.3 Global Kidney Cancer Drugs Sales Market Share by Application (2020-2031)
5.2 Global Kidney Cancer Drugs Revenue by Application (2020-2031)
5.2.1 Global Kidney Cancer Drugs Revenue by Application (2020-2025)
5.2.2 Global Kidney Cancer Drugs Revenue by Application (2026-2031)
5.2.3 Global Kidney Cancer Drugs Revenue Market Share by Application (2020-2031)
5.3 Global Kidney Cancer Drugs Price by Application (2020-2031)
6 Key Companies Profiled
6.1 Bayer
6.1.1 Bayer Company Information
6.1.2 Bayer Description and Business Overview
6.1.3 Bayer Kidney Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.1.4 Bayer Kidney Cancer Drugs Product Portfolio
6.1.5 Bayer Recent Developments/Updates
6.2 Roche
6.2.1 Roche Company Information
6.2.2 Roche Description and Business Overview
6.2.3 Roche Kidney Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Roche Kidney Cancer Drugs Product Portfolio
6.2.5 Roche Recent Developments/Updates
6.3 GlaxoSmithKline
6.3.1 GlaxoSmithKline Company Information
6.3.2 GlaxoSmithKline Description and Business Overview
6.3.3 GlaxoSmithKline Kidney Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.3.4 GlaxoSmithKline Kidney Cancer Drugs Product Portfolio
6.3.5 GlaxoSmithKline Recent Developments/Updates
6.4 Novartis
6.4.1 Novartis Company Information
6.4.2 Novartis Description and Business Overview
6.4.3 Novartis Kidney Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Novartis Kidney Cancer Drugs Product Portfolio
6.4.5 Novartis Recent Developments/Updates
6.5 Pfizer
6.5.1 Pfizer Company Information
6.5.2 Pfizer Description and Business Overview
6.5.3 Pfizer Kidney Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Pfizer Kidney Cancer Drugs Product Portfolio
6.5.5 Pfizer Recent Developments/Updates
6.6 Abbott Laboratories
6.6.1 Abbott Laboratories Company Information
6.6.2 Abbott Laboratories Description and Business Overview
6.6.3 Abbott Laboratories Kidney Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Abbott Laboratories Kidney Cancer Drugs Product Portfolio
6.6.5 Abbott Laboratories Recent Developments/Updates
6.7 Active Biotech
6.7.1 Active Biotech Company Information
6.7.2 Active Biotech Description and Business Overview
6.7.3 Active Biotech Kidney Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Active Biotech Kidney Cancer Drugs Product Portfolio
6.7.5 Active Biotech Recent Developments/Updates
6.8 Amgen
6.8.1 Amgen Company Information
6.8.2 Amgen Description and Business Overview
6.8.3 Amgen Kidney Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Amgen Kidney Cancer Drugs Product Portfolio
6.8.5 Amgen Recent Developments/Updates
6.9 Argos Therapeutics
6.9.1 Argos Therapeutics Company Information
6.9.2 Argos Therapeutics Description and Business Overview
6.9.3 Argos Therapeutics Kidney Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Argos Therapeutics Kidney Cancer Drugs Product Portfolio
6.9.5 Argos Therapeutics Recent Developments/Updates
6.10 ArQule
6.10.1 ArQule Company Information
6.10.2 ArQule Description and Business Overview
6.10.3 ArQule Kidney Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.10.4 ArQule Kidney Cancer Drugs Product Portfolio
6.10.5 ArQule Recent Developments/Updates
6.11 AVEO Pharmaceuticals
6.11.1 AVEO Pharmaceuticals Company Information
6.11.2 AVEO Pharmaceuticals Description and Business Overview
6.11.3 AVEO Pharmaceuticals Kidney Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.11.4 AVEO Pharmaceuticals Kidney Cancer Drugs Product Portfolio
6.11.5 AVEO Pharmaceuticals Recent Developments/Updates
6.12 Bionomics
6.12.1 Bionomics Company Information
6.12.2 Bionomics Description and Business Overview
6.12.3 Bionomics Kidney Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Bionomics Kidney Cancer Drugs Product Portfolio
6.12.5 Bionomics Recent Developments/Updates
6.13 Bristol-Myers Squibb
6.13.1 Bristol-Myers Squibb Company Information
6.13.2 Bristol-Myers Squibb Description and Business Overview
6.13.3 Bristol-Myers Squibb Kidney Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Bristol-Myers Squibb Kidney Cancer Drugs Product Portfolio
6.13.5 Bristol-Myers Squibb Recent Developments/Updates
6.14 Cerulean Pharma
6.14.1 Cerulean Pharma Company Information
6.14.2 Cerulean Pharma Description and Business Overview
6.14.3 Cerulean Pharma Kidney Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Cerulean Pharma Kidney Cancer Drugs Product Portfolio
6.14.5 Cerulean Pharma Recent Developments/Updates
6.15 Exelixis
6.15.1 Exelixis Company Information
6.15.2 Exelixis Description and Business Overview
6.15.3 Exelixis Kidney Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Exelixis Kidney Cancer Drugs Product Portfolio
6.15.5 Exelixis Recent Developments/Updates
6.16 Genentech
6.16.1 Genentech Company Information
6.16.2 Genentech Description and Business Overview
6.16.3 Genentech Kidney Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.16.4 Genentech Kidney Cancer Drugs Product Portfolio
6.16.5 Genentech Recent Developments/Updates
6.17 immatics biotechnologies
6.17.1 immatics biotechnologies Company Information
6.17.2 immatics biotechnologies Description and Business Overview
6.17.3 immatics biotechnologies Kidney Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.17.4 immatics biotechnologies Kidney Cancer Drugs Product Portfolio
6.17.5 immatics biotechnologies Recent Developments/Updates
6.18 Immunicum
6.18.1 Immunicum Company Information
6.18.2 Immunicum Description and Business Overview
6.18.3 Immunicum Kidney Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.18.4 Immunicum Kidney Cancer Drugs Product Portfolio
6.18.5 Immunicum Recent Developments/Updates
6.19 Ono Pharmaceutical
6.19.1 Ono Pharmaceutical Company Information
6.19.2 Ono Pharmaceutical Description and Business Overview
6.19.3 Ono Pharmaceutical Kidney Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.19.4 Ono Pharmaceutical Kidney Cancer Drugs Product Portfolio
6.19.5 Ono Pharmaceutical Recent Developments/Updates
6.20 Onyx Therapeutics
6.20.1 Onyx Therapeutics Company Information
6.20.2 Onyx Therapeutics Description and Business Overview
6.20.3 Onyx Therapeutics Kidney Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.20.4 Onyx Therapeutics Kidney Cancer Drugs Product Portfolio
6.20.5 Onyx Therapeutics Recent Developments/Updates
6.21 Oxford BioMedica
6.21.1 Oxford BioMedica Company Information
6.21.2 Oxford BioMedica Description and Business Overview
6.21.3 Oxford BioMedica Kidney Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.21.4 Oxford BioMedica Kidney Cancer Drugs Product Portfolio
6.21.5 Oxford BioMedica Recent Developments/Updates
6.22 Prometheus Laboratories
6.22.1 Prometheus Laboratories Company Information
6.22.2 Prometheus Laboratories Description and Business Overview
6.22.3 Prometheus Laboratories Kidney Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.22.4 Prometheus Laboratories Kidney Cancer Drugs Product Portfolio
6.22.5 Prometheus Laboratories Recent Developments/Updates
6.23 Seattle Genetics
6.23.1 Seattle Genetics Company Information
6.23.2 Seattle Genetics Description and Business Overview
6.23.3 Seattle Genetics Kidney Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.23.4 Seattle Genetics Kidney Cancer Drugs Product Portfolio
6.23.5 Seattle Genetics Recent Developments/Updates
6.24 Taiwan Liposome
6.24.1 Taiwan Liposome Company Information
6.24.2 Taiwan Liposome Description and Business Overview
6.24.3 Taiwan Liposome Kidney Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.24.4 Taiwan Liposome Kidney Cancer Drugs Product Portfolio
6.24.5 Taiwan Liposome Recent Developments/Updates
6.25 Tracon Pharmaceuticals
6.25.1 Tracon Pharmaceuticals Company Information
6.25.2 Tracon Pharmaceuticals Description and Business Overview
6.25.3 Tracon Pharmaceuticals Kidney Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.25.4 Tracon Pharmaceuticals Kidney Cancer Drugs Product Portfolio
6.25.5 Tracon Pharmaceuticals Recent Developments/Updates
6.26 Wilex
6.26.1 Wilex Company Information
6.26.2 Wilex Description and Business Overview
6.26.3 Wilex Kidney Cancer Drugs Sales, Revenue and Gross Margin (2020-2025)
6.26.4 Wilex Kidney Cancer Drugs Product Portfolio
6.26.5 Wilex Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Kidney Cancer Drugs Industry Chain Analysis
7.2 Kidney Cancer Drugs Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Kidney Cancer Drugs Production Mode & Process Analysis
7.4 Kidney Cancer Drugs Sales and Marketing
7.4.1 Kidney Cancer Drugs Sales Channels
7.4.2 Kidney Cancer Drugs Distributors
7.5 Kidney Cancer Drugs Customer Analysis
8 Kidney Cancer Drugs Market Dynamics
8.1 Kidney Cancer Drugs Industry Trends
8.2 Kidney Cancer Drugs Market Drivers
8.3 Kidney Cancer Drugs Market Challenges
8.4 Kidney Cancer Drugs Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
Bayer
Roche
GlaxoSmithKline PLC
Novartis
Pfizer Inc
Abbott Laboratories
Active Biotech
Amgen Inc
Argos Therapeutics
ArQule Inc
AVEO Pharmaceuticals
Bionomics Ltd
Bristol–Myers Squibb
Cerulean Pharma
Exelixis Inc
Immatics Biotechnologies
Immunicum
Ono Pharmaceutical
Onyx Therapeutics
Oxford BioMedica
Prometheus Laboratories
Seattle Genetics
Taiwan Liposome
Tracon Pharmaceuticals
Wilex
Genentech Inc
List of Tables
 Table 1. Global Kidney Cancer Drugs Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Kidney Cancer Drugs Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Kidney Cancer Drugs Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Kidney Cancer Drugs Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Kidney Cancer Drugs Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Kidney Cancer Drugs Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Kidney Cancer Drugs Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Kidney Cancer Drugs Average Price (USD/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Kidney Cancer Drugs, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Kidney Cancer Drugs, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Kidney Cancer Drugs, Product Type & Application
 Table 12. Global Key Manufacturers of Kidney Cancer Drugs, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Kidney Cancer Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Kidney Cancer Drugs as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Kidney Cancer Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Kidney Cancer Drugs Sales by Region (2020-2025) & (K Units)
 Table 18. Global Kidney Cancer Drugs Sales Market Share by Region (2020-2025)
 Table 19. Global Kidney Cancer Drugs Sales by Region (2026-2031) & (K Units)
 Table 20. Global Kidney Cancer Drugs Sales Market Share by Region (2026-2031)
 Table 21. Global Kidney Cancer Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Kidney Cancer Drugs Revenue Market Share by Region (2020-2025)
 Table 23. Global Kidney Cancer Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Kidney Cancer Drugs Revenue Market Share by Region (2026-2031)
 Table 25. North America Kidney Cancer Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Kidney Cancer Drugs Sales by Country (2020-2025) & (K Units)
 Table 27. North America Kidney Cancer Drugs Sales by Country (2026-2031) & (K Units)
 Table 28. North America Kidney Cancer Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Kidney Cancer Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Kidney Cancer Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Kidney Cancer Drugs Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Kidney Cancer Drugs Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Kidney Cancer Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Kidney Cancer Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Kidney Cancer Drugs Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Kidney Cancer Drugs Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Kidney Cancer Drugs Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Kidney Cancer Drugs Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Kidney Cancer Drugs Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Kidney Cancer Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Kidney Cancer Drugs Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Kidney Cancer Drugs Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Kidney Cancer Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Kidney Cancer Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Kidney Cancer Drugs Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Kidney Cancer Drugs Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Kidney Cancer Drugs Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Kidney Cancer Drugs Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Kidney Cancer Drugs Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Kidney Cancer Drugs Sales (K Units) by Type (2020-2025)
 Table 51. Global Kidney Cancer Drugs Sales (K Units) by Type (2026-2031)
 Table 52. Global Kidney Cancer Drugs Sales Market Share by Type (2020-2025)
 Table 53. Global Kidney Cancer Drugs Sales Market Share by Type (2026-2031)
 Table 54. Global Kidney Cancer Drugs Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Kidney Cancer Drugs Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Kidney Cancer Drugs Revenue Market Share by Type (2020-2025)
 Table 57. Global Kidney Cancer Drugs Revenue Market Share by Type (2026-2031)
 Table 58. Global Kidney Cancer Drugs Price (USD/Unit) by Type (2020-2025)
 Table 59. Global Kidney Cancer Drugs Price (USD/Unit) by Type (2026-2031)
 Table 60. Global Kidney Cancer Drugs Sales (K Units) by Application (2020-2025)
 Table 61. Global Kidney Cancer Drugs Sales (K Units) by Application (2026-2031)
 Table 62. Global Kidney Cancer Drugs Sales Market Share by Application (2020-2025)
 Table 63. Global Kidney Cancer Drugs Sales Market Share by Application (2026-2031)
 Table 64. Global Kidney Cancer Drugs Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Kidney Cancer Drugs Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Kidney Cancer Drugs Revenue Market Share by Application (2020-2025)
 Table 67. Global Kidney Cancer Drugs Revenue Market Share by Application (2026-2031)
 Table 68. Global Kidney Cancer Drugs Price (USD/Unit) by Application (2020-2025)
 Table 69. Global Kidney Cancer Drugs Price (USD/Unit) by Application (2026-2031)
 Table 70. Bayer Company Information
 Table 71. Bayer Description and Business Overview
 Table 72. Bayer Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 73. Bayer Kidney Cancer Drugs Product
 Table 74. Bayer Recent Developments/Updates
 Table 75. Roche Company Information
 Table 76. Roche Description and Business Overview
 Table 77. Roche Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 78. Roche Kidney Cancer Drugs Product
 Table 79. Roche Recent Developments/Updates
 Table 80. GlaxoSmithKline Company Information
 Table 81. GlaxoSmithKline Description and Business Overview
 Table 82. GlaxoSmithKline Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 83. GlaxoSmithKline Kidney Cancer Drugs Product
 Table 84. GlaxoSmithKline Recent Developments/Updates
 Table 85. Novartis Company Information
 Table 86. Novartis Description and Business Overview
 Table 87. Novartis Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 88. Novartis Kidney Cancer Drugs Product
 Table 89. Novartis Recent Developments/Updates
 Table 90. Pfizer Company Information
 Table 91. Pfizer Description and Business Overview
 Table 92. Pfizer Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 93. Pfizer Kidney Cancer Drugs Product
 Table 94. Pfizer Recent Developments/Updates
 Table 95. Abbott Laboratories Company Information
 Table 96. Abbott Laboratories Description and Business Overview
 Table 97. Abbott Laboratories Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 98. Abbott Laboratories Kidney Cancer Drugs Product
 Table 99. Abbott Laboratories Recent Developments/Updates
 Table 100. Active Biotech Company Information
 Table 101. Active Biotech Description and Business Overview
 Table 102. Active Biotech Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 103. Active Biotech Kidney Cancer Drugs Product
 Table 104. Active Biotech Recent Developments/Updates
 Table 105. Amgen Company Information
 Table 106. Amgen Description and Business Overview
 Table 107. Amgen Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 108. Amgen Kidney Cancer Drugs Product
 Table 109. Amgen Recent Developments/Updates
 Table 110. Argos Therapeutics Company Information
 Table 111. Argos Therapeutics Description and Business Overview
 Table 112. Argos Therapeutics Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 113. Argos Therapeutics Kidney Cancer Drugs Product
 Table 114. Argos Therapeutics Recent Developments/Updates
 Table 115. ArQule Company Information
 Table 116. ArQule Description and Business Overview
 Table 117. ArQule Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 118. ArQule Kidney Cancer Drugs Product
 Table 119. ArQule Recent Developments/Updates
 Table 120. AVEO Pharmaceuticals Company Information
 Table 121. AVEO Pharmaceuticals Description and Business Overview
 Table 122. AVEO Pharmaceuticals Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 123. AVEO Pharmaceuticals Kidney Cancer Drugs Product
 Table 124. AVEO Pharmaceuticals Recent Developments/Updates
 Table 125. Bionomics Company Information
 Table 126. Bionomics Description and Business Overview
 Table 127. Bionomics Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 128. Bionomics Kidney Cancer Drugs Product
 Table 129. Bionomics Recent Developments/Updates
 Table 130. Bristol-Myers Squibb Company Information
 Table 131. Bristol-Myers Squibb Description and Business Overview
 Table 132. Bristol-Myers Squibb Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 133. Bristol-Myers Squibb Kidney Cancer Drugs Product
 Table 134. Bristol-Myers Squibb Recent Developments/Updates
 Table 135. Cerulean Pharma Company Information
 Table 136. Cerulean Pharma Description and Business Overview
 Table 137. Cerulean Pharma Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 138. Cerulean Pharma Kidney Cancer Drugs Product
 Table 139. Cerulean Pharma Recent Developments/Updates
 Table 140. Exelixis Company Information
 Table 141. Exelixis Description and Business Overview
 Table 142. Exelixis Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 143. Exelixis Kidney Cancer Drugs Product
 Table 144. Exelixis Recent Developments/Updates
 Table 145. Genentech Company Information
 Table 146. Genentech Description and Business Overview
 Table 147. Genentech Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 148. Genentech Kidney Cancer Drugs Product
 Table 149. Genentech Recent Developments/Updates
 Table 150. immatics biotechnologies Company Information
 Table 151. immatics biotechnologies Description and Business Overview
 Table 152. immatics biotechnologies Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 153. immatics biotechnologies Kidney Cancer Drugs Product
 Table 154. immatics biotechnologies Recent Developments/Updates
 Table 155. Immunicum Company Information
 Table 156. Immunicum Description and Business Overview
 Table 157. Immunicum Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 158. Immunicum Kidney Cancer Drugs Product
 Table 159. Immunicum Recent Developments/Updates
 Table 160. Ono Pharmaceutical Company Information
 Table 161. Ono Pharmaceutical Description and Business Overview
 Table 162. Ono Pharmaceutical Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 163. Ono Pharmaceutical Kidney Cancer Drugs Product
 Table 164. Ono Pharmaceutical Recent Developments/Updates
 Table 165. Onyx Therapeutics Company Information
 Table 166. Onyx Therapeutics Description and Business Overview
 Table 167. Onyx Therapeutics Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 168. Onyx Therapeutics Kidney Cancer Drugs Product
 Table 169. Onyx Therapeutics Recent Developments/Updates
 Table 170. Oxford BioMedica Company Information
 Table 171. Oxford BioMedica Description and Business Overview
 Table 172. Oxford BioMedica Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 173. Oxford BioMedica Kidney Cancer Drugs Product
 Table 174. Oxford BioMedica Recent Developments/Updates
 Table 175. Prometheus Laboratories Company Information
 Table 176. Prometheus Laboratories Description and Business Overview
 Table 177. Prometheus Laboratories Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 178. Prometheus Laboratories Kidney Cancer Drugs Product
 Table 179. Prometheus Laboratories Recent Developments/Updates
 Table 180. Seattle Genetics Company Information
 Table 181. Seattle Genetics Description and Business Overview
 Table 182. Seattle Genetics Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 183. Seattle Genetics Kidney Cancer Drugs Product
 Table 184. Seattle Genetics Recent Developments/Updates
 Table 185. Taiwan Liposome Company Information
 Table 186. Taiwan Liposome Description and Business Overview
 Table 187. Taiwan Liposome Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 188. Taiwan Liposome Kidney Cancer Drugs Product
 Table 189. Taiwan Liposome Recent Developments/Updates
 Table 190. Tracon Pharmaceuticals Company Information
 Table 191. Tracon Pharmaceuticals Description and Business Overview
 Table 192. Tracon Pharmaceuticals Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 193. Tracon Pharmaceuticals Kidney Cancer Drugs Product
 Table 194. Tracon Pharmaceuticals Recent Developments/Updates
 Table 195. Wilex Company Information
 Table 196. Wilex Description and Business Overview
 Table 197. Wilex Kidney Cancer Drugs Sales (K Units), Revenue (US$ Million), Price (USD/Unit) and Gross Margin (2020-2025)
 Table 198. Wilex Kidney Cancer Drugs Product
 Table 199. Wilex Recent Developments/Updates
 Table 200. Key Raw Materials Lists
 Table 201. Raw Materials Key Suppliers Lists
 Table 202. Kidney Cancer Drugs Distributors List
 Table 203. Kidney Cancer Drugs Customers List
 Table 204. Kidney Cancer Drugs Market Trends
 Table 205. Kidney Cancer Drugs Market Drivers
 Table 206. Kidney Cancer Drugs Market Challenges
 Table 207. Kidney Cancer Drugs Market Restraints
 Table 208. Research Programs/Design for This Report
 Table 209. Key Data Information from Secondary Sources
 Table 210. Key Data Information from Primary Sources
 Table 211. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Kidney Cancer Drugs
 Figure 2. Global Kidney Cancer Drugs Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Kidney Cancer Drugs Market Share by Type: 2024 & 2031
 Figure 4. Angiogenesis Inhibitors Product Picture
 Figure 5. mTOR Inhibitors Product Picture
 Figure 6. Monoclonal Antibodies Product Picture
 Figure 7. Cytokine Immunotherapy (IL-2) Product Picture
 Figure 8. Global Kidney Cancer Drugs Market Value by Application (2020-2031) & (US$ Million)
 Figure 9. Global Kidney Cancer Drugs Market Share by Application: 2024 & 2031
 Figure 10. Renal Cell Carcinoma (RCC)
 Figure 11. Transitional Cell Carcinoma (TCC)
 Figure 12. Global Kidney Cancer Drugs Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 13. Global Kidney Cancer Drugs Market Size (2020-2031) & (US$ Million)
 Figure 14. Global Kidney Cancer Drugs Sales (2020-2031) & (K Units)
 Figure 15. Global Kidney Cancer Drugs Average Price (USD/Unit) & (2020-2031)
 Figure 16. Kidney Cancer Drugs Report Years Considered
 Figure 17. Kidney Cancer Drugs Sales Share by Manufacturers in 2024
 Figure 18. Global Kidney Cancer Drugs Revenue Share by Manufacturers in 2024
 Figure 19. Global 5 and 10 Largest Kidney Cancer Drugs Players: Market Share by Revenue in Kidney Cancer Drugs in 2024
 Figure 20. Kidney Cancer Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 21. Global Kidney Cancer Drugs Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 22. North America Kidney Cancer Drugs Sales Market Share by Country (2020-2031)
 Figure 23. North America Kidney Cancer Drugs Revenue Market Share by Country (2020-2031)
 Figure 24. U.S. Kidney Cancer Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 25. Canada Kidney Cancer Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 26. Europe Kidney Cancer Drugs Sales Market Share by Country (2020-2031)
 Figure 27. Europe Kidney Cancer Drugs Revenue Market Share by Country (2020-2031)
 Figure 28. Germany Kidney Cancer Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. France Kidney Cancer Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. U.K. Kidney Cancer Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Italy Kidney Cancer Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 32. Russia Kidney Cancer Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 33. Asia Pacific Kidney Cancer Drugs Sales Market Share by Region (2020-2031)
 Figure 34. Asia Pacific Kidney Cancer Drugs Revenue Market Share by Region (2020-2031)
 Figure 35. China Kidney Cancer Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. Japan Kidney Cancer Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. South Korea Kidney Cancer Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. India Kidney Cancer Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Australia Kidney Cancer Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Taiwan Kidney Cancer Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 41. Indonesia Kidney Cancer Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 42. Thailand Kidney Cancer Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Malaysia Kidney Cancer Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Philippines Kidney Cancer Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Latin America Kidney Cancer Drugs Sales Market Share by Country (2020-2031)
 Figure 46. Latin America Kidney Cancer Drugs Revenue Market Share by Country (2020-2031)
 Figure 47. Mexico Kidney Cancer Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Brazil Kidney Cancer Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. Argentina Kidney Cancer Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. Middle East and Africa Kidney Cancer Drugs Sales Market Share by Country (2020-2031)
 Figure 51. Middle East and Africa Kidney Cancer Drugs Revenue Market Share by Country (2020-2031)
 Figure 52. Turkey Kidney Cancer Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 53. Saudi Arabia Kidney Cancer Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 54. U.A.E Kidney Cancer Drugs Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 55. Global Sales Market Share of Kidney Cancer Drugs by Type (2020-2031)
 Figure 56. Global Revenue Market Share of Kidney Cancer Drugs by Type (2020-2031)
 Figure 57. Global Kidney Cancer Drugs Price (USD/Unit) by Type (2020-2031)
 Figure 58. Global Sales Market Share of Kidney Cancer Drugs by Application (2020-2031)
 Figure 59. Global Revenue Market Share of Kidney Cancer Drugs by Application (2020-2031)
 Figure 60. Global Kidney Cancer Drugs Price (USD/Unit) by Application (2020-2031)
 Figure 61. Kidney Cancer Drugs Value Chain
 Figure 62. Channels of Distribution (Direct Vs Distribution)
 Figure 63. Bottom-up and Top-down Approaches for This Report
 Figure 64. Data Triangulation
 Figure 65. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Seventh Sense AI

SIMILAR REPORTS

Kidney Cancer Medicine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Kidney Cancer or Renal Cancer Market Research Report 2024
Renal Cell Cancer Treatment Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Kidney Cancer Therapeutics Market Research Report 2025
Global Kidney Cancer and Renal Cell Carcinoma RCC Drugs Market Insights Forecast to 2030
Kidney Cancer Diagnostics Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Kidney Cancer Therapeutics and Diagnostics Market Insights Forecast to 2030
Global Kidney Cancer Market Research Report 2025
Global Kidney Cancer Therapy Market Research Report 2024
Renal Cell Carcinoma Therapy Devices Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Urothelial Cancer Drugs Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Cancer Drug Therapy Market Insights Forecast to 2030
Global Renal Diseases Drug Market Insights Forecast to 2030
Global Renal Therapeutic Market Research Report 2025
Urinary Tract Cancer Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global End Stage Renal Disease Market Research Report 2024
Global Kidney Cancer Molecular Diagnostics Market Research Report 2024
Global Ovarian Cancer Market Research Report 2024
Basal Cell Carcinoma Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Renal Cell Cacinoma Drugs Market Research Report 2024
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions